Full text: Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Click Here for Original Story

NEWS PROVIDED BY

Creative Medical Technology Holdings, Inc.
Sep 26, 2022, 08:00 ET

--Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine® Procedure for Treating Chronic Lower Back Pain --

PHOENIX, Sept. 26, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, today announced the peer reviewed publication of positive, two-year follow-up data for the Company's StemSpine® study, showing significant efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.

The StemSpine® publication demonstrates the clinical use of the patented procedure that utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain. There were no safety related concerns at up to two years follow-up. The StemSpine® procedure resulted in an efficacy rate of 87% in the treated patients in terms of decreased pain and increased mobility.

"The positive two-year data from our StemSpine® study is very encouraging and may help alleviate the current opioid crisis related to prescription medication abuse for chronic lower back pain," said Timothy Warbington, President and CEO of the Company. "To our knowledge, this is the first demonstration of the clinical efficacy of injecting bone marrow aspirate into areas surrounding the disc, which may repair, remodel and improve the blood supply around the disc and lower back area. We believe StemSpine® represents an attractive non-surgical option for many of the millions of Americans who suffer from chronic lower back pain and look forward to further translation."

The StemSpine® patent also covers the use of off the shelf adult donor stem cells (allogeneic) for this indication.

The publication may be found at www.creativemedicaltechnology.com.

About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a biotechnology company specializing in regenerative medicine in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com.

Forward Looking Statements
This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov

SOURCE Creative Medical Technology Holdings, Inc.

CELZ files FORM 8-K JULY 8, 2022


Celz files FORM 8-K - CLICK HERE TO READ ENTIRE 8-K FILING

Basically it says:

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 8, 2022, Creative Medical Technology Holdings, Inc. (the “Company”) received a letter from The Nasdaq Stock Market stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days. The notice has no immediate impact on the Company’s listing.

Pursuant to Nasdaq’s Listing Rules, the Company has a 180 day grace period, until January 4, 2023, during which the Company may regain compliance if the bid price of its common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. The Company may be eligible for an additional 180-day grace period if the Company meets Nasdaq’s initial listing standards (other than with respect to minimum bid price) for The Nasdaq Capital Market.

The Company intends to actively monitor the bid price for its common stock between now and January 4, 2023, and will consider available options to regain compliance with the Nasdaq minimum bid price requirements.

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

Click below to read article from PR Newswire (US) June 15 2022 - 08:30AM

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

PHOENIX, June 15, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced pluripotent stem cell (iPSC) pipeline for the Company's ImmCelz® platform. This project will be identified as iPScelzTM for future reference.

Creative Medical Technology Holdings, Inc. Logo (PRNewsfoto/Creative Medical Technology Hol)

Dr. Joseph C. Wu, co-founder of Greenstone Biosciences remarks, "This is a great collaboration that translates our expertise in iPSC technology to accelerate therapies that improve patient care – fast-tracking bench to bedside." Dr. Wu is the Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine & Radiology at Stanford University.

Timothy Warbington, President and CEO of the Company, commented, "We are excited to complement and expand our current work with the addition of Dr. Joseph Wu and the Greenstone team at Alexandria Center for Life Sciences (ACLS). Greenstone brings extensive experience in the development of iPSC and related technologies. In combination with work continuing at the University of Miami, we believe that our ImmCelz® platform has enormous potential to improve outcomes for patients across multiple indications, including Stroke, Type I Diabetes, Heart Disease, Liver Disease, and Kidney Disease."

Human iPSc's are genetically reprogrammed to differentiate into a wide array of human cell and tissue types, possess the ability to proliferate almost indefinitely in culture, and represent a single source of cells that could be used to replace those lost to damage or disease. Beyond the therapeutic benefits offered by iPSC, the next generation iPScelzTM pipeline for ImmCelz® will enable the ability for large scale production and sustainability, while helping to reduce long term costs of manufacturing.

About ImmCelz®
ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming "cocktail", the cells are re-injected back into the patient. These "supercharged" cells subsequently "educate" other cells of the immune system to stop attacking the body, while preserving the ability to attack foreign pathogens.

About Greenstone Biosciences
Greenstone Biosciences, Inc. (Palo Alto, CA) is a biotechnology company co-founded by Joseph C. Wu, MD, PhD and Jade Chao, JD, MPH. The biotech company specializes in clinical genomics, iPSC technology, AI/ML, and drug development. Greenstone has extensive knowledge and expertise in generating patient-derived human iPSCs and differentiate to numerous cell types for disease modeling and drug discovery. Greenstone Board Chairman Lip-Bu Tan of Walden Catalyst Venture (WCV) is a long-term strategic partner. Mr. Tan considers "this a wonderful and strategic partnership with CELZ." For further information, please visit www.greenstonebio.com.

About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com.

Forward Looking Statements
This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-agreement-with-greenstone-biosciences-inc-for-development-of-a-next-generation-ipsc-pipeline-for-its-immcelz-immunotherapy-platform-301568167.html

SOURCE Creative Medical Technology Holdings, Inc.


Copyright 2022 PR Newswire

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Click below to read the full report from Sec.gov EDGAR
Form 4 filed June 14 2022 .... CLICK HERE


SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Finger Michael H.
(Last) (First) (Middle)
1551 N. DIANE ST.
(Street)
MESA AZ 85203-3850
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. [ CELZ ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/14/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/14/2022 P 10,000 A $0.7 16,502 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Michael H. Finger 06/14/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

NEWS .... Notice of Exempt Offering of Securities


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D
Notice of Exempt Offering of Securities

CLICK HERE TO VIEW

News FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 29, 20228-K

iClick Here to Read

News

Click to Read

RW 1 celz_rw.htm RW
Creative Medical Technology Holdings, Inc.
211 E. Osborn Road
Phoenix, Arizona 85012



May 4, 2022
Via Edgar

Mr. Daniel Crawford
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549


Re:

Creative Medical Technology Holdings, Inc.

Request for Withdrawal of Registration Statement on Form S-1
Filed April 22, 2022
File No. 333-264455


Dear Ms. Crawford:


Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Creative Medical Technology Holdings, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement be withdrawn, effective as of the date hereof. The Company is withdrawing the Registration Statement because it no longer plans to consummate the offering of its securities described in the Registration Statement. The Registration Statement has not been declared effective by the Securities and Exchange Commission (the “SEC”), and no securities have been issued or sold thereunder. Accordingly, the Company believes that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors.


The Company requests that, in accordance with Rule 457(p) of the Securities Act and subject to compliance with the requirements thereof, all fees paid to the SEC in connection with the filing of the Registration Statement be credited for future use.


Please contact Zev M. Bomrind of Fox Rothschild LLP, counsel to the Company, at (212) 878-7951, if you have any questions or concerns regarding this matter.




Sincerely,
/s/ Timothy Warbington
Timothy Warbington
Chief Executive Officer

Form S-1 Filed on April 22, 2022

Form S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

See below:

Click Here to read form S-1

Click Here to read SEC.GOV Edgar

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

CLICK HERE to read CISION PR Newswire

NEWS PROVIDED BY

Creative Medical Technology Holdings, Inc.
Apr 20, 2022, 08:30 ET

-- Initial experiments demonstrate expeditious potential for high-volume production of ImmCelz® with consistent potency --

PHOENIX, April 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which the ImmCelz® product was produced in less than 72 hours, utilizing the Company's cell-free supercharging solution. The amount of ImmCelz® produced was significantly greater than the control in numerous replicates of the experiments. There was also the ability to verify repeated potency of the final ImmCelz® product.

Timothy Warbington, President and CEO of the Company, commented, "We are excited to receive this great news, which further validates our immunotherapy platform and sets the stage for advancing clinical studies. We look forward to continuing to work closely with team members at the University of Miami who bring decades of combined experience to our projects. We believe that our Immcelz® program has enormous potential to improve outcomes for patients across multiple indications, including stroke, Type I diabetes, heart disease, liver disease, and kidney disease."

About ImmCelz®

ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming "cocktail", the cells are re-injected back into the patient. These "supercharged" cells subsequently "educate" other cells of the immune system to stop attacking the body, while preserving the ability to attack foreign pathogens.

The Company plans to advance multiple indications for ImmCelz® starting with stroke, which is currently under FDA review. Upon successful approval to proceed with clinical trials for stroke, the Company anticipates accelerating additional therapies under the ImmCelz® umbrella, including for Type I diabetes, heart disease, liver disease, and kidney disease.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com.

Forward Looking Statements

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

Creative Medical Technology
Company Contact IR@CreativeMedicalTechnology.com

Investor Relations
The Equity Group Inc.
Kalle Ahl, CFA
(212) 836-9614
kahl@equityny.com

Devin Sullivan
(212) 836-9608
dsullivan@equityny.com

SOURCE Creative Medical Technology Holdings, Inc.

Amendment No. 2 to Form S-1/A

Click here: Amendment No. 2 to Form S-1/A

What's with the new address:
211 E Osborn Road
Phoenix, AZ 85012
Click Below:
New Address ?

Creative Medical Technology Holdings Reports Positive Data on ImmCelz™ Immunotherapy Product

Company Achieves Selective Reprogramming of Pathological Autoimmunity

Creative Medical Technology Holdings, Inc.
Oct 12, 2021, 08:15 ET

LINKED HERE:
Creative Medical Technology Holdings Reports Positive Data on ImmCelz™ Immunotherapy Product

Contents of info:

PHOENIX, Oct. 12, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings Inc. announced today proof of concept data demonstrating the ability of its next generation ImmCelz™ immunotherapy product to "reprogram" patient immune cells using the Company's patent pending "ex vivo cell-free" reprogramming protocol.

The study was performed at cGMP Advanced Cell and Biologic Products Manufacturing Facility of the Diabetes Research Institute, Cell Transplant Center at the University of Miami, Miami FL and was supported by The Cure Alliance, a non-profit research organization.

ImmCelz™, which is protected by trade secrets and published US patents, utilizes adult stem cells derived from qualified donors, to endow specific properties to patient immune cells. After the patient immune cells are incubated with our cell-free reprogramming cocktail, the immune cells are extracted and re-injected back into the patient. These "reprogrammed cells" subsequently "educate" other cells of the immune system to stop attacking the body, while preserving the ability to attack cancers and foreign pathogens.

The ability to use cell-free reprogramming is a giant leap for using patient specific immune therapies. "The data disclosed today, suggest the ability of ImmCelz™ to achieve superior results in a manner which is amenable to safe, scalable and rapid clinical translation," said Dr. Camillo Ricordi, member of the Company's Scientific Advisory Board and Director of the Diabetes Research Institute.

"Immunotherapy represents a revolution in medicine in which cells of the immune system are being developed as drugs," said Timothy Warbington, President and CEO of the Company. "While the majority of efforts are focused on stimulation of immunity, for treatment of cancer and viruses, our ImmCelz™ product represents a novel platform aimed at selective suppression of harmful immune responses."

ImmCelz™ has been demonstrated effective in animal models of autoimmunity and is currently the subject of a pending IND filed by the Company with the FDA for the treatment of stroke victims.

Harmful immune responses, otherwise known as autoimmunity, are a multibillion dollar market which comprises conditions such as type 1 diabetes, stroke, rheumatoid arthritis, kidney and liver disease and potentially many other indications.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in immunotherapy, neurology, urology and orthopedics and is currently listed on the OTC under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.

Forward-Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

https://caverstem.com/

https://femcelz.com/

http://www.stemspine.com/

https://immcelz.com/

SOURCE Creative Medical Technology Holdings, Inc.


Related Links
http://creativemedicaltechnology.com

Celz News today September 24, 2021

Information Statement - All Other (definitive) (def 14c)
September 24 2021 - 04:05PM
Edgar (US Regulatory)


Apparently just some more of the same "CELZ B.S."

CELZ to Launch Virtual Physician™ Focused on Telehealth Solutions for Regenerative Medicine

News provided by
Creative Medical Technology Holdings, Inc.
Mar 23, 2021, 07:45 ET


Click Here to Read


PHOENIX, March 23, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced its intent to launch Virtual Physician™ focused on telehealth solutions for regenerative medicine this summer.

The company will initially utilize the platform to educate, recruit and retain patients for their already commercialized proprietary procedures in partnership with their national network of providers:

CaverStem®: Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men

FemCelz®: Regenerative Stem Cell Procedure for Vaginal Rejuvenation

As additional products are commercialized, (i.e. StemSpine® - Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease), the platform will expand to include these products.

Furthermore, the company plans to build out Virtual Physician™ to include additional products outside of their proprietary procedures focused on regenerative medicine. "While our primary interest is in supporting our providers and to educate, recruit and retain patients for our proprietary procedures through this innovative platform, we are also aware of the power of telehealth to accelerate acceptance for regenerative medicine more broadly", said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc. "While several telehealth companies have emerged (i.e. Teladoc with market cap of $29B; HIMS & HERS Health with market cap of $2.5B), none address this area of breakthrough medicine. As a company at the forefront of this cutting-edge industry, we see it as our responsibility to drive broad adoption."

Virtual Physician creates three unique opportunities to drive shareholder value:

Management Service Organization (MSO): Charging a fee per qualified patient to providers – conversations with existing providers validates this as highly valuable

Royalty for promotion of products from external partners:. As the platform grows in popularity, company can charge a fee from other manufacturers for featuring their products

Direct sales of ancillary products to consumers on platform: Become a one-stop shop for our patients by curating and consolidating additional products to improve underlying medical conditions

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine-stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

www.CreativeMedicalTechnology.com
www.CaverStem.com
www.FemCelz.com
www.StemSpine.com

SOURCE Creative Medical Technology Holdings, Inc.
Related Links

creativemedicaltechnology.com

That was for another procedure but I wanted the Creative Medical Technology equipment to be used in that procedure ... only on my back.

That doc's office didn't have the equipment as I was told he would, (Doc office said they would use CELZ equipment). Therefore I never actually had any procedure from this doc.

Looking up the doc's credentials I found many complaints on the internet and good/bad/indifferent found most to not really appreciate some work this doc had performed.

In short I believe that CELZ revoked any permission for this doc to use their medical equipment.

Truth is probably in the eyes of the beholder. I read lots of toss around words used over and over again. Actually best to do your own Due Diligence on CELZ and read not only what is on this board but anything else you can find on the company. This is just one opinion amongst many. You decide. Long term, short tern, invest, don't invest ... only decisions you can make.

Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®

CLICK HERE Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®

Company Aims to Leverage Immune Modulatory Technology to Alleviate Need for Immune Suppressants after Transplantation

News provided by
Creative Medical Technology Holdings, Inc.

Feb 16, 2021, 07:45 ET

Share this article

PHOENIX, Feb. 16, 2021 /PRNewswire/ -- (OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today filing of a patent application covering the use of ImmCelz® regenerative cell therapy for preventing rejection of transplanted organs. ImmCelz® is a cellular therapy that prevents pathological immunity and inflammation while at the same time inducing regeneration of damaged tissue. Mechanistically ImmCelz® has been shown to function through stimulation of T regulatory cells1 and producing the regenerative protein Hepatocyte Growth Factor (HGF)2. The patent demonstrates that ImmCelz® may have the potential to inhibit chronic graft rejection, which is the major cause of organ loss.

"The concept of immunological tolerance has been around for more than a Century since the days of Peter Medawar," said Dr. Amit Patel, Board Member of the Company and co-inventor of the patent. "Unfortunately, transplant recipients, which include some of my patients, need to take global immune suppressive medication to reduce immune-mediated rejection of the organ. These medications, despite having made organ transplantation a reality, have potential side effects including various infections due to suppression of immunity. ImmCelz® is being developed to induce immunological tolerance, which if achieved would allow for organ transplantation without need for continuous immune suppression."

Sales of immune suppressants, which are used after transplants to prevent patients from rejecting their organs exceeded 4 billion dollars in 20183.

"To date the Company has reported therapeutic activity of ImmCelz® in models of rheumatoid arthritis4, stroke5, type 1 diabetes6, kidney failure7 and liver failure8," said Timothy Warbington, President and CEO of the Company. "Demonstration of enhancing graft survival in organ transplantation allows for a whole new area of medical progress. Our scientists suggest the superior efficacy of ImmCelz® for organ transplantation is that the cellular therapy suppresses rejection, while at the same time regenerates the organ after transplantation. It is known that the process of transplantation causes harm to the organ."

"It is our goal to continue to broaden our intellectual property portfolio by patenting technologies that our scientific team determines to be worthwhile and in the area of our core concentration," Mr. Warbington said further.

About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com.

Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

Creativemedicaltechnology.com
www.StemSpine.com
www.Femcelz.com
www.ImmCelz.com
www.OvaStem.com

1 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)
2 Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity (prnewswire.com)
3 Organ Transplant Immunosuppressant Drugs Market Size Report, 2026 (grandviewresearch.com)
4 Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model | BioSpace
5 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)
6 Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes (prnewswire.com)
7 Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz® Regenerative Immunotherapy (prnewswire.com)
8 Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model | Nasdaq

SOURCE Creative Medical Technology Holdings, Inc.
Related Links

http://www.creativemedicaltechnology.com

CELZ update posted on Facebook:


Creative Medical Technology Holdings Inc.


Creative Medical Technology Holdings Inc.
46 mins ·

To all CELZ investors, we've received inquiries about the status of the IND application and speculations on the timing of a response. Our team members have been involved with numerous FDA applications over the years so we understand that deadlines are not necessarily written in stone. The FDA just like all of us may be effected by the pandemic with many people working from home and perhaps with somewhat of a backlog. This should not be perceived as positive or negative. Patience is the key. We are waiting for a response and once we hear back we will make the proper public disclosure. In the mean time, our team is continuing to work on our diverse portfolio. It's business as usual for us. Thank you to all that have inquired.

Creative Medical Technology Holdings Inc.

Nicely Done. Up 159% .. GLTA Much more to come for CELZ. Bitcoin may be up but but maybe only 1.5% today. Bitcoin is too rich for me but definitely not CELZ !!!

HAPPY NEW YEAR EVERYBODY !!!! ENJOY THE DAY OFF .... 2021 WHOHOOOO

What a Great New Year's Eve ... Have a Great New Year's Day .... makes me want to buy another million shares of CELZ $$$$. hahaha. Good news all around.

I had no idea what that profile was saying so I had Google translate help me.

Hopefully to get English translation:

Click on this link:

English translation of Creative Medical technical analysis

https://translate.google.com/translate?hl=en&sl=auto&tl=en&u=https%3A%2F%2Fnl.investing.com%2Fequities%2Fcreative-medical-technical

Merry Christmas all.

Great description of the state of affairs for CMTH.

Well, it seems like CMTH must be on top of their game ... going to seek FDA approval. Must be up to something really big here with IMMCELZ. Go CELZ !

You got it. Bingo ! Go CELZ

Looks that way to me.

IMMCELZ™ Adoptive Immunotherapy Product isn't a drug. Search the press release for the word "drug". Hint: It's not there.

That's right folks, unlike a "drug", "IMMCELZ™ product specifically reprograms cells of the immune system in order to specifically stop attack against the body's own tissues, while preserving immune responses against cancer and infectious diseases."


Press Release Line

Quote:

Creative Medical Technology Holdings Announces IMMCELZ™ Adoptive Immunotherapy Product

Clinical Stage Adult Stem Cell Therapy Company Discovers New Way to Stop Immune Diseases without Immune Suppression

NEWS PROVIDED BY
Creative Medical Technology Holdings, Inc.
Mar 11, 2020, 08:15 ET
PHOENIX, March 11, 2020 /PRNewswire/ -- Creative Medical Technology Holdings announced today, what appears to be, the first personalized adoptive immunotherapy for treatment of autoimmunity, which the Company named "IMMCELZ™".

Utilizing the newly discovered properties of regenerative cells to alter immune cells, the Company has found a new method of developing "patient-specific" treatments for diseases in which the immune system pathologically starts to attack healthy tissues in the body, a state termed "autoimmunity".

The autoimmune disease market is estimated to be approximately $38 billion annually1. Common autoimmune diseases include Type 1 diabetes, Rheumatoid arthritis, Psoriasis/Psoriatic arthritis, Multiple sclerosis, Systemic lupus erythematous (lupus), Inflammatory bowel diseases, Myasthenia gravis, Vasculitis, Celiac disease and Hashimoto's Thyroiditis.

"Current drugs treating autoimmunity act to suppress the immune system globally, thus increasing the risks of infections and cancers," said Dr. Thomas Ichim, Chief Scientific Officer of the Company and Co-Inventor of the technology. "In contrast, the IMMCELZ™ product specifically reprograms cells of the immune system in order to specifically stop attack against the body's own tissues, while preserving immune responses against cancer and infectious diseases."

IMMCELZ™, which is protected by trade secrets and published US patent application 15/987739, utilizes adult stem cells derived from qualified donors, to endow specific properties to patient immune cells. After the patient immune cells are incubated with the donor stem cells, the immune cells are extracted and re-injected back into the patient. These "reprogrammed cells" subsequent "educate" other cells of the immune system to stop attacking the body, while preserving ability to attack cancers and foreign pathogens.

"While the results are preliminary, and additional research is needed before clinical trials may begin, we believe that the current interest in cellular immunotherapy, will turn in using these types of approaches for treatment of autoimmunity," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "Examples of cellular immunotherapies for cancer include CAR-T cells developed by Kite Pharma, which was acquired by Gilead for $11.9 Billion2. Our corporate philosophy is that cells are intrinsically superior therapeutics to chemical drugs, and we believe our entry into the field of autoimmunity will delivery a higher level of therapeutic effect in autoimmunity as compared to conventional approaches."

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.

Forward-Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at https://www.sec.gov.

Timothy Warbington, CEO

www.Creativemedicaltechnology.com

https://caverstem.com

https://femcelz.com

http://www.stemspine.com

1 https://www.marketwatch.com/press-release/autoimmune-disease-market-industry-outlook-size-forecast-2018-2025-2019-10-22

2 https://uk.reuters.com/article/uk-kite-pharma-m-a-gilead-sciences/gilead-to-buy-kite-for-promising-cancer-therapies-in-12-billion-deal-idUKKCN1B810W

SOURCE Creative Medical Technology Holdings, Inc.


Related Links

https://creativemedicaltechnology.com

Cool, I saw that too.

Facebook page: Creative Medical Technology Holdings to present results from CaverStem publication at international conference in Peru on Saturday, March 14, 2020 at Hotel Country Club.
Link: Link to Facebook post

Conference Details:
PDF in Spanish

I’ve cut and pasted the actual PDF information below from the PDF download and including the highlights related to CELZ, highlighted and bolded them, underlined and then translated to the best the highlights and what pertains to Dr. Amit Patel and a few other items. Here goes:

8va CONFERENCIA INTERNACIONAL DE TERAPIA CELULAR DEL PACIFICO SUR
Translatlion: (This is the 8th INTERNATIONAL CONFERENCE OF SOUTH PACIFIC CELLULAR THERAPY)

8:15 - 8:20 AM
MODERADOR:
8:30 – 9:00 AM
9:00 – 9:30 AM
09:30 – 10:00 AM
10:00 – 10:30 AM
10:30 - 11:00 AM
11:00 – 11:30 AM
11:30 – 12:00 AM
PASION POR LA INNOVACION translation: (PASSION FOR INNOVATION)
AGENDA
SABADO 27 DE AGOSTO DEL 2016 HOTEL COUNTRY CLUB
PALABRAS DE BIENVENIDA Translation: (Welcome Words)
Dr. Jorge Tuma, Lima-Perú
Director del Instituto de Autotransfusión de Células Autologas INACEL
(Translation: Dr. Jorge Tuma, Lima-Peru
Director of the Autologous Cell Autotransfusion Institute INACEL)

PALABRAS DEL PAST PRESIDENT Asociacion Peruana de Terapia Celular Dr. Jorge Castillo APETECEL
Translation: (Director of the Autologous Cell Autotransfusion Institute INACEL
WORDS OF THE PAST PRESIDENT Peruvian Association of Cell Therapy Dr. Jorge Castillo APETECEL)[/b]

SESION 1
DR. JORGE CASTILLO DR. JORGE TUMA
DR. RUBEN DULANTO
TERAPIA CELULAR PARA LA DIABETES MELLITUS Dr. Roberto Fernandez Viña ARGENTINA
TERAPIA CELULAR PARA LA FIBROSIS PULMONAR Dr. Amit Patel EEUU
Translation: (CELLULAR THERAPY FOR PULMONARY FIBROSIS Dr. Amit Patel EEUU)
PLASMA RICO EN PLAQUETAS PARA LA ENFERMEDAD ARTICULAR Dr.Mikel Sanchez ESPAÑA
TERAPIA CELULAR PARA LA CIRROSIS HEPATICA Dr. Jorge Tuma. PERU
TERAPIA CELULAR PARA LA ENFERMEDAD DE PARKINSON Dr. Augusto Brazzini PERU
TERAPIA CELULAR PARA LA ENFERMEDAD MACULAR Dr. Raul Vargas PERU
PLASMA RICO EM PLAQUETAS PARA EL FOLICULO PILOSO Dr. Ramzey Mubarak PERU
COFFEA BREAK
MODERADOR:
1:00- 1:30PM 1:30- 2:00PM 2:00 - 2:30 PM 2:30 – 3:00 PM
3:00 PM
SESION 2
DR. ROBERTO FERNANDEZ VIÑA DR. CARLOS YARLEQUE
TERAPIA CELULAR PARA LA INSUFICIENCIA VASCULAR PERIFERICA Dr. Amit Patel EEUU
Translation: (CELLULAR THERAPY FOR PERIPHERAL VASCULAR INSUFFICIENCY Dr. Amit Patel EEUU)
TERAPIA CELULAR PARA EL INFARTO AGUDO AL MIOCARDIO Dr. Tim Henry EEUU
TERAPIA CELULAR PARA LA INSUFICIENCIA CARDIACA Dr. Roberto Fernandez Viña ARGENTINA
CONFERENCIA MAGISTRAL 13 años de seguimiento Dr .Amit Patel EEUU
Translation: (MAGISTRAL CONFERENCE 13 years of follow-up Dr. Amit Patel EEUU)
PALABRAS FINALES Translation: (Final Words)
Dr. Roberto Fernandez Viña
ALMUERZO Translation: (Lunch)

CaverStem®, is a stem cell therapy for Erectile Dysfunction (ED) that utilizes the patient’s own stem cells to repair damaged or degrading penile tissue. 9 million men in the US who suffer from ED receive no benefit from Viagra/Cialis or have side effects that limit usage. The cause of ED is damaged smooth muscle tissue and surrounding blood vessels in the penis caused by disease or injury. Medications do NOT address the underlying cause of ED the way that CaverStem does. Our proprietary, outpatient procedure uses stem cells harvested from a patient’s own bone marrow to regenerate damaged tissue.

I believe the technology works from what I've heard and read about CaverStem, FemCelz, AmnioStem and StemSpine and the research they've conducted. Patents CMTH holds hold promise. All this needs to transform into sustainable revenue.

CMTH's communication skills need to improve.

CMTH does need a forceful impact statement of operations along with honest evaluation/assessment and disclosure concerning any existing and extended business plans they may have that can be measured in anticipated revenues for shareholders. Plain and simple ... shareholders deal in numbers that we can see and trust.

Notes do need to be refinanced without loan shark lenders, toxic or spiral financing. Will there be enough revenue to extinguish notes? <<< Management answer this.

Anticipation is one thing we've (as shareholders) have been well exposed for over two years, however, shareholders expect CMTH's performance to pay off and produce sufficient and significant numbers not only to fund existing costs but to pay off those notes.

CMTH, please let us know what type of refinancing your existing notes and future financing notes will be. Give us good financial reasons to invest in CELZ/CELZD.

CMTH definitely needs to expand their base of physicians in areas currently not served in the United States. I can understand the Southwest area being served as their proximity to CMTH is pretty close. Although Florida, Hawaii and a clinic in Italy serve clients, there lacks market presence in the Northwest, Mid and Upper West, Northeast and mid-Atlantic.

Hopefully some of these new physicians coming aboard will begin to disperse for easier client access. Hopefully CMTH will exceed revenues quarter over quarter by significant numbers.

Yes, CMTH needs improvement, no question about it in my view. We shall see.

Spot on +1000. I wish management would listen to their shareholders.

No, circles and ovals do nothing for me except in Geometry, I also don't believe in underlines, highlights and CORRECT ?? on opinion websites. Goodbye.

Ohh, btw: "This Official Record was reported on October 16, 2018. The person named in this listing has only been arrested on suspicion of the crime indicated and is presumed innocent" <<< probably just a lie ... I mean who in the world would get arrested for some presumed crime and not be utterly guilty. (sigh). ...

CORRECT ?? <<<< see it does nothing for me when discussing CELZ/CELZD.

Seriously don't see any notation like "01/31/2020 Amendment After Issuance of Stock" on the website:

https://esos.nv.gov/EntitySearch/BusinessInformation

Link. But you have to be registered in order to access this website

Home page of SilverFlume to Access This website for the Nevada Secretary of State you must register here first

Maybe they don't have the change(s) yet ???
Must be a lie by Nevada Secretary of State ?

Hmmmm ??? Remembering the claim of not having their Annual Report reflective of a renewal ??? That surely was a CELZ lie ? CORRECT? HUH ???

Entity Name: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC
Entity Number: C28165-1998
Entity Type: Domestic Corporation (78)
Entity Status: Active
Formation Date: 12/03/1998
NV Business ID: NV19981395139
Termination Date: Perpetual
Annual Report Due Date: 12/31/2020


CORRECT ???

Could be a lot of risk with CELZ on this play but ..."Be fearful when others are greedy, and greedy when others are fearful," said famed billionaire value investor Warren Buffett, a phrase that encapsulates the contrarian philosophy. So, with that in mind, I'll skip my weekly trip to the Foxwoods this weekend, invest $200 tomorrow on a million shares of CELZ (depending on the pps), then take the dog for a walk.

I don't have a problem with the technology or patents held by CMTH, just some management move(s)/decision(s). Other investors or non-investors may have other motives or incentives to invest or not, , but whatever they are, they're clearly not entirely mine. I take responsibility for my own decisions and not others on any opinion board.

Good Luck to All but whenever investing, make sure you do your own research and due diligence before investing because in the end, if you choose to do so, either win or lose, it's your money, not mine.

Monte379, great summary. I agree with most everything you stated.

I began following CELZ perhaps a little later than you but around May of 2018. I read lot of anticipatory opinions of Due Diligence from a lot of folks attempting to calculate the future revenues that didn’t seem that plausible but I invested in the company and the potential that I saw in CELZ, not in other folks exuberant DD or their projections of revenue in such a short period of time.

Knowing that this is a startup company I understood that it would take quite a long time from a Convention they were going to attend to the actual commercialization of their products. I saw investors coming in with breakneck speed and raising the pps in an odd fashion because the product was too new and really CELZ was not bringing in the revenue to support such a rise in PPS that appeared impulsive. At that period, around or just under one cent was my thought at the time because the proposed commercialization of CELZ really hadn’t begun in earnest but held a lot of promise. CELZ is still ,in my mind, with CaverStem, FemCelz and now StemSpine and other procedures building upon other patents holding a lot of promise for the future, not now, but hopefully within a few years.

The last company they started “Medistem” appeared to be a success and rewarded shareholders very well. In one email to CELZ that was answered, the company did NOT express concern with the pps as it fell from .07 to .03 and was not prepared to speak about the granularity of the pps. However we now see as the pps evaporated an anticipated r/s situation where CELZ will supposedly attempt to bring that pps to one cent. We’ll have to see if that happens.

CELZ has a product and technology, patents and research making this portion of CELZ a pretty good investment. I still see CELZ’s technology as a great thing, but the realistic timeline has had bumps in the road and the outlook for other countries performing the procedures, aside from the US and Italy, like Russia has withered. I wish CELZ would give investors updated information about other countries prospect. CELZ clinical trials appeared to come at glacial speed for many, but that’s how these trials play out. They’re not all alike, some are quicker than others, but CELZ clinical trials now have some published results showing a safe and effective treatment.

CELZ’s continued financing with toxic notes is totally unfortunate to say the least. I do wonder if this proposed 150:1 r/s will take place. My guess is yes but I guess we’ll have to wait and see.

I still do not see CELZ as a scam or fraud, but anybody can opine otherwise unendingly as that is their prerogative. Others can continue pointing out to either stock or financing as lies and show us website captures and whatever and on an on, but CELZ has never been investigated for fraud or corruption by any regulatory authority thus I just don’t believe all that B.S. Yelling B.S. a million times simply does not make it so. All the diversionary B.S. about CELZ is just that, nothing but diversion and more of an illusion. Future investors should take all that B.S. into account. I'm not talking about the pps, that's a different story.

CELZ continues to show promising technology for the future and that’s still uncharted territory. I’m in this for the technology, patents and kits that are eventually bought. The more the better. Obviously, I wish for more kits to be sold for more procedures performed and more doctors trained. Maybe with the clinical trials published, CELZ can move forward in that direction.

Wow, best of luck with your holdings.

In my opinion ... Zero. Not one public investigation by SEC saying CELZ was in violation of the federal securities laws. If you can find one, please let us all know.

Maybe it's just me but I'll take the word of the SEC over any opinion cited on this board specifically regarding CELZ being in violation of the federal securities laws.

Hey, it's your opinion and your more than entitled to it.

My thoughts really ? Ok if everything's a lie ... tell me why they're still in business, their website is active, still selling kits and there are no active trading suspensions and all that bullturd, Nevada website still shows "active". I guess that's all a lie too. My guess is that it's not a lie. But I'm not judge, jury and executioner I've been hearing about "lying" beginning about a year or more ago from sources around the internet re: CELZ. But of course, it's just the internet.

Then realizing of course that this is just an opinion board everyone has to conduct their own due diligence and form their own opinion(s), I'd leave that up to themselves.. So that in brief sums up my "thoughts".

My other thought is that it's now dinner time and I'm hungry. So I'm taking a timeout. Have Fun with your "opinions" everybody.

weeeeeeeeeeeeeeeeeeeee

Geez, why did we change the subject all of a sudden ? There must be some fogginess about the Nevada Secretary of State's website and the Nevada State Statutes, hah ?

status: active

Somebody, please let me when they see the website changed. Yeah.